Conclusions
ELN, AML
AML
In summary, this retrospective analysis shows no significant benefit of high-dose cytarabine compared to intermediate dosages in consolidation for AML patients under 65 years of age, independent of ELN risk group. Our results contribute to the growing body of evidence indicating similar efficacy of IDAC and HiDAC consolidation with slightly better tolerability. While evidence on the implications on CBF AML is limited, these real-word data underpin a recommendation for the use of IDAC rather than HiDAC in consolidation chemotherapy.